DaVita (NYSE:DVA) Price Target Cut to $113.00

DaVita (NYSE:DVA) had its target price reduced by UBS Group from $142.00 to $113.00 in a research report report published on Friday, Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently issued reports on the stock. Truist Financial lowered their price objective on shares of DaVita from $115.00 to $104.00 and set a hold rating for the company in a research note on Wednesday, October 11th. TheStreet cut shares of DaVita from a b- rating to a c rating in a research note on Monday, October 23rd. Finally, StockNews.com started coverage on shares of DaVita in a research note on Thursday, October 5th. They set a buy rating for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $102.67.

DaVita Stock Up 1.4 %

DVA stock opened at $97.53 on Friday. The stock has a market capitalization of $8.90 billion, a P/E ratio of 14.96, a PEG ratio of 0.63 and a beta of 0.98. The company has a debt-to-equity ratio of 6.01, a quick ratio of 1.19 and a current ratio of 1.24. DaVita has a one year low of $69.55 and a one year high of $116.97. The company has a 50 day moving average price of $87.84 and a two-hundred day moving average price of $95.93.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, November 7th. The company reported $2.85 EPS for the quarter, topping the consensus estimate of $1.92 by $0.93. DaVita had a net margin of 5.11% and a return on equity of 63.38%. The firm had revenue of $3.12 billion during the quarter, compared to analysts’ expectations of $3.02 billion. During the same period in the previous year, the company earned $1.45 EPS. DaVita’s revenue for the quarter was up 5.9% on a year-over-year basis. As a group, sell-side analysts expect that DaVita will post 8.17 EPS for the current year.

Hedge Funds Weigh In On DaVita

A number of institutional investors have recently added to or reduced their stakes in DVA. Norges Bank acquired a new position in DaVita in the 4th quarter worth $116,373,000. Deutsche Bank AG raised its stake in shares of DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after purchasing an additional 885,195 shares in the last quarter. Amundi raised its stake in shares of DaVita by 226.3% in the 4th quarter. Amundi now owns 659,372 shares of the company’s stock valued at $52,592,000 after purchasing an additional 457,285 shares in the last quarter. Wedge Capital Management L L P NC raised its stake in shares of DaVita by 6,031.9% in the 2nd quarter. Wedge Capital Management L L P NC now owns 366,813 shares of the company’s stock valued at $36,854,000 after purchasing an additional 360,831 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of DaVita by 37.9% in the 4th quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock valued at $92,042,000 after purchasing an additional 339,051 shares in the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.